<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01939587</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-PBF-2013-93</org_study_id>
    <secondary_id>2013-002906-30</secondary_id>
    <nct_id>NCT01939587</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics</brief_title>
  <official_title>A Single-centre, Randomised, Double-blind, Placebo-controlled, 3-way Multiple Dose, Cross-over, &quot;Proof-of-concept&quot; Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate (AMP) Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Palo Biofarma, S.L</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, double-blind, randomized trial utilizing a three-period, balanced&#xD;
      block design, with each period comprising a unique study product administration. The&#xD;
      treatments studied are PBF-680 5 mg, PBF-680 20 mg and placebo, as an orally administered&#xD;
      capsule. The study includes a screening visit, a selection visit, three visits for the&#xD;
      randomized treatment sequence, and an end-of-study follow-up visit, spanning through a 65-day&#xD;
      maximum study duration. The study will be conducted on 18 male or female adults aged ³18&#xD;
      years, with a diagnosis of stable, mild to moderate asthma as per GINA guidelines, with no&#xD;
      smoking or less than a 5 packs-years smoking history history, responsive to AMP airway&#xD;
      challenge as determined in the selection visit.&#xD;
&#xD;
      The primary efficacy variable will be the PC20 yielded from AMP airway challenge testing at&#xD;
      the three treatment visits. FeNO, sampled at three time points at each treatment period&#xD;
      visit, will be a exploratory variable. Safety assessment will include monitoring of adverse&#xD;
      events, physical examination, vital signs, EKGs, spirometry, serum and urine pregnancy tests,&#xD;
      and laboratory determinations. Blood sampling at a time-point series will provide&#xD;
      pharmacokinetics data.&#xD;
&#xD;
      The primary variable of the study is PC20, mg×mL-1. The PC 20 distributions will be analyzed&#xD;
      by treatment using ANOVA for repeated measurements, followed by post hoc pairwise comparisons&#xD;
      as appropriate. Other analyses will comprise FeNO, pharmacokinetics, data sets generated from&#xD;
      baseline characteristics and safety assessments, and discretionary expiratory analyses to&#xD;
      evaluate the influence of baseline and clinical covariates on the primary variable.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PC20 yielded from AMP airway challenge testing</measure>
    <time_frame>2.25, 3.5, 8 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>PBF-680 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg of PBF-680</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBF-680 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg of PBF-680</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBF-680 5 mg</intervention_name>
    <arm_group_label>PBF-680 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBF-680 20 mg</intervention_name>
    <arm_group_label>PBF-680 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adults aged 18, who have signed the informed consent form prior to&#xD;
             initiation of any study procedures.&#xD;
&#xD;
          -  Subjects with mild to moderate asthma, diagnosed as per Global Initiative for&#xD;
             Asthma(GINA) guidelines.&#xD;
&#xD;
          -  Subjects must have a body mass index between 18 and 35 kg/m².&#xD;
&#xD;
          -  Subjects must be able to perform acceptable spirometry in accordance with ATS/ERS&#xD;
             criteria for acceptability repeatability.&#xD;
&#xD;
          -  Subjects must have a baseline FEV1 60% of predicted normal, and greater than 1 L in&#xD;
             absolute value, on Visit 2.&#xD;
&#xD;
          -  On Visit 2, eligible subjects must show airway hyperresponsiveness to AMP, determined&#xD;
             by PC20 thresholding (the AMP provocative concentration that elicits a 20% drop from&#xD;
             baseline FEV1 value, under AMP challenge test as per the ERS Task Force on Indirect&#xD;
             Airway Challenges).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current smokers, smokers within six months prior to Visit 1, or subjects with an&#xD;
             smoking history greater than 5 pack-years.&#xD;
&#xD;
          -  Asthmatics in treatment Step 5 as per GINA guidelines, including oral corticosteroids&#xD;
             and/or omalizumab, or any immunosuppressive medication whether asthma-related or&#xD;
             indicated for any concomitant morbidities.&#xD;
&#xD;
          -  Subjects with a history of life-threatening asthma attacks (i.e. requiring ICU&#xD;
             admission, orotracheal intubation).&#xD;
&#xD;
          -  Subjects with a history of a respiratory tract infection or an asthma crisis requiring&#xD;
             the use of antibiotics and/or systemic corticosteroids within 4 weeks prior to Visit&#xD;
             1, or who develop a respiratory tract infection or asthma crisis during the screening&#xD;
             period. In the latter case, the subjects can be re-screened four weeks after the last&#xD;
             dose of systemic corticosteroid or antibiotic.&#xD;
&#xD;
          -  Subjects that received bronchial thermoplastic treatment.&#xD;
&#xD;
          -  Subjects with concomitant pulmonary or thoracic disease other than asthma that could&#xD;
             interfere safety or efficacy as per site investigator assessment. This includes, but&#xD;
             is not limited to, COPD attributable to tobacco or alpha-1 antitrypsin deficiency,&#xD;
             cystic fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension,&#xD;
             active pulmonary tuberculosis, or any prior condition that led to pulmonary resection&#xD;
             surgery or lung transplantation. Non-cystic fibrosis bronchiectasis without clinically&#xD;
             significant morbidity, moderate alpha-1 antitrypsin deficiency without evidence of&#xD;
             emphysema or related COPD, or past pulmonary tuberculosis that received proper medical&#xD;
             treatment, are acceptable provided that the condition is not expected to interfere&#xD;
             with pulmonary function testing as per site investigator assessment.&#xD;
&#xD;
          -  Subjects with symptoms of angina pectoris or with a history of confirmed coronary&#xD;
             disease or cardiomyopathy.&#xD;
&#xD;
          -  Subjects with A-V block in any degree, sinus bradycardia, tachyarrhythmia, unstable&#xD;
             atrial fibrillation, long QT syndrome, QTc(F) interval greater than 450 ms at&#xD;
             screening(Visit 2), or any other EKG abnormality deemed clinically significant by the&#xD;
             investigator.&#xD;
&#xD;
          -  Subjects who have a clinically significant laboratory abnormality at screening (Visit&#xD;
             2).&#xD;
&#xD;
          -  Subjects with current uncontrolled arterial hypertension.&#xD;
&#xD;
          -  Women of child-bearing potential, unless they are surgically sterile (i.e. bilateral&#xD;
             tubal ligation, bilateral oophorectomy, or complete hysterectomy), are at least 2&#xD;
             years postmenopausal, practice abstinence, or agree to employ effective contraception&#xD;
             from Visit 1 through Visit 6. Acceptable contraception procedures are oral,&#xD;
             transdermal, or implanted contraceptives, intrauterine device, female condom with&#xD;
             spermicide, diaphragm with spermicide, or use of a condom with spermicide by the&#xD;
             sexual partner.&#xD;
&#xD;
          -  Women supplying lactation.&#xD;
&#xD;
          -  Receipt of any investigational drug therapy or biologicals within 3 months before&#xD;
             randomization in this study, or within 5 half-lives of the investigational agent or&#xD;
             biologic, whichever is longer.&#xD;
&#xD;
          -  History of any known immunodeficiency disorder.&#xD;
&#xD;
          -  Subjects with a history of malignancy within the past five years, with the exception&#xD;
             of localized basal cell carcinoma of the skin.&#xD;
&#xD;
          -  History of treatment for alcohol or drug abuse within the past year.&#xD;
&#xD;
          -  Subjects with any comorbidity that could affect the safety or efficacy as per site&#xD;
             investigator assessment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Palobiofarma S.L. (molecule owner)</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <zip>08302</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.iibsantpau.cat/</url>
    <description>Institut d'Investigació Biomèdica Sant Pau</description>
  </link>
  <link>
    <url>http://www.palobiofarma.com/</url>
    <description>molecule owner</description>
  </link>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>August 8, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2013</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenosine A1 receptor antagonist</keyword>
  <keyword>Asthma</keyword>
  <keyword>adenosine receptor modulator</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

